Close Menu

NGeneBio Raises $11M

NEW YORK (GenomeWeb) – Korean diagnostics firm NGeneBio said this week that it recently closed an $11 million Series B financing.

The company also achieved a CE-IVD mark for its HEMEaccuTest, which targets hematological malignancies, according to YoungJoon Moon, director of business development for the Seoul-based company.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
17

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.